Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTR T Cells + Trastuzumab in HER2+ Advanced Malignancies
NCT03680560Phase 1Terminated
- Sponsor
- Cogent Biosciences
- Start
- Mar 2019
- Primary completion
- Mar 2020
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ACTR707 and ACTR087 in HER2-positive solid tumor (HER2+), sponsored by Cogent Biosciences. Primary endpoints: Safety and tolerability of ACTR T cell product with trastuzumab at 42 days and Determination of recommended phase 2 dose at 42 days. Started Mar 2019; status: terminated.
02
Drugs
ACTR707ACTR087
03
Conditions
HER2-positive solid tumor (HER2+)
Beyond the preview
Go deeper on NCT03680560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03680560.